Form 8-K - Current report:
SEC Accession No. 0001214659-21-009969
Filing Date
2021-09-30
Accepted
2021-09-30 16:30:32
Documents
14
Period of Report
2021-09-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 c9302118k.htm   iXBRL 8-K 26792
2 EXHIBIT 99.1 ex99_1.htm EX-99.1 9390
3 GRAPHIC image_001.jpg GRAPHIC 22371
  Complete submission text file 0001214659-21-009969.txt   245027

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE alzn-20210930.xsd EX-101.SCH 3001
5 XBRL LABEL FILE alzn-20210930_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE alzn-20210930_pre.xml EX-101.PRE 22343
7 EXTRACTED XBRL INSTANCE DOCUMENT c9302118k_htm.xml XML 3706
Mailing Address 3802 SPECTRUM BLVD, SUITE C112C TAMPA FL 33612
Business Address 3802 SPECTRUM BLVD, SUITE C112C TAMPA FL 33612 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 211295399
SIC: 2834 Pharmaceutical Preparations